Der blev lavet en anden populationsfarmakokinetisk analyse, hvori der indgik erlotinibdata fra 204 patienter med pancreas- cancer, som fik erlotinib plus gemcitabin.
A second population pharmacokinetic analysis was conducted that incorporated erlotinib data from 204 pancreatic cancer patients who received erlotinib plus gemcitabine.